Global Quetiapine Fumarate Market Growth 2019-2024

Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
The Quetiapine Fumarate was developed by AstraZeneca from 1992 to 1996. It was first approved by the FDA in 1997.
The product is invented and first produced in the UK by AstraZeneca. AstraZeneca is also the leader of the Quetiapine Fumarate base drugs.
The Average gross of the industry is over 40%. However, since there are new companies coming into the area, the gross is declining in the last several years.

According to this study, over the next five years the Quetiapine Fumarate market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Quetiapine Fumarate business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Quetiapine Fumarate market by product type, application, key manufacturers and key regions and countries.

This study considers the Quetiapine Fumarate value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Immediate Release Tablets
Extended Release Tablets
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Application I
Application II

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AstraZeneca
Intas
TAPI
Accord
Hexal
Dr.Reddy's
Lupin
Sun Pharmaceutical
Hunan Dongting Pharm
SuZhou NO.4 Phamaceutical Factory
Fuan Pharmaceutical
Zhejiang Supor Pharmaceuticals
Zhejiang Huahai Pharmaceutical

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Quetiapine Fumarate consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Quetiapine Fumarate market by identifying its various subsegments.
Focuses on the key global Quetiapine Fumarate manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Quetiapine Fumarate with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Quetiapine Fumarate submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.